{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:40:58Z","timestamp":1777952458291,"version":"3.51.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["A18-1052"],"award-info":[{"award-number":["A18-1052"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jinf.2026.106737","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T07:33:46Z","timestamp":1773992026000},"page":"106737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Residual HIV viremia strongly increases cardiovascular disease incidence independent of classical risk factors"],"prefix":"10.1016","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2880-9111","authenticated-orcid":false,"given":"Twan","family":"Otten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8846-957X","authenticated-orcid":false,"given":"Suzanne D.E.","family":"Ruijten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc J.T.","family":"Blaauw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4423-3012","authenticated-orcid":false,"given":"Mareva","family":"Delporte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Navas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilhelm A.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert L.","family":"Groenendijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise E.","family":"van Eekeren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadira","family":"Vadaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Hageman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki","family":"Matzaraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3923-1478","authenticated-orcid":false,"given":"Olivier","family":"Richel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin","family":"Berrevoets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2242-8342","authenticated-orcid":false,"given":"Annelies","family":"Verbon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1486-3045","authenticated-orcid":false,"given":"Janneke","family":"Stalenhoef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Arts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan van","family":"Lunzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9197-8124","authenticated-orcid":false,"given":"Niels P.","family":"Riksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linos","family":"Vandekerckhove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihai G.","family":"Netea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 J.","family":"van der Ven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jinf.2026.106737_bib1","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","article-title":"Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies","volume":"10","author":"Trickey","year":"2023","journal-title":"Lancet HIV"},{"issue":"4","key":"10.1016\/j.jinf.2026.106737_bib2","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S2352-3018(20)30036-9","article-title":"HIV and cardiovascular disease","volume":"7","author":"So-Armah","year":"2020","journal-title":"Lancet HIV"},{"issue":"34","key":"10.1016\/j.jinf.2026.106737_bib3","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jinf.2026.106737_bib4","first-page":"407","article-title":"HIV and cardiovascular disease: from insights to interventions","volume":"29","author":"Feinstein","year":"2021","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.jinf.2026.106737_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2022.102186","article-title":"Navigating the complexity of chronic HIV-1 associated immune dysregulation","volume":"76","author":"Boyd","year":"2022","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1016\/j.jinf.2026.106737_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12981-016-0105-z","article-title":"What happens to cardiovascular system behind the undetectable level of HIV viremia?","volume":"13","author":"d\u2019Ettorre","year":"2016","journal-title":"AIDS Res Ther"},{"issue":"1","key":"10.1016\/j.jinf.2026.106737_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/aid.2014.0194","article-title":"Potential implication of residual viremia in patients on effective antiretroviral therapy","volume":"31","author":"Sahu","year":"2015","journal-title":"AIDS Res Hum Retrovir"},{"issue":"11","key":"10.1016\/j.jinf.2026.106737_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113876","article-title":"Association of residual plasma viremia and intima-media thickness in antiretroviral-treated patients with controlled human immunodeficiency virus infection","volume":"9","author":"Boyd","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jinf.2026.106737_bib9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jinf.2026.106737_bib10","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1097\/QAD.0000000000003240","article-title":"Associations between HIV viremia during antiretroviral therapy and cardiovascular disease","volume":"36","author":"Elvstam","year":"2022","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.jinf.2026.106737_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf016","article-title":"Viremia does not independently predict cardiovascular disease in people with HIV: a respond cohort study","volume":"12","author":"Elvstam","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.jinf.2026.106737_bib12","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1016\/S2352-3018(25)00047-5","article-title":"Statin use in HIV: European AIDS Clinical Society guidance for the primary prevention of cardiovascular disease","volume":"12","author":"Alagaratnam","year":"2025","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jinf.2026.106737_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663843","article-title":"Residual viremia is linked to a specific immune activation profile in HIV-1-infected adults under efficient antiretroviral therapy","volume":"12","author":"Younas","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jinf.2026.106737_bib14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-3083.2008.02184.x","article-title":"Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies\/ml is associated with increased blood levels of soluble immune activation markers","volume":"68","author":"Ostrowski","year":"2008","journal-title":"Scand J Immunol"},{"issue":"1","key":"10.1016\/j.jinf.2026.106737_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/infdis\/jis630","article-title":"Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells","volume":"208","author":"Hatano","year":"2013","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2026.106737_bib16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1186\/s12879-017-2676-2","article-title":"Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns","volume":"17","author":"Falasca","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"11","key":"10.1016\/j.jinf.2026.106737_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026320","article-title":"Association of low level viremia with inflammation and mortality in HIV-infected adults","volume":"6","author":"Eastburn","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jinf.2026.106737_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1628086","article-title":"No associations between HIV reservoir and inflammation in long-term virally suppressed dolutegravir-based ART-treated individuals","volume":"16","author":"Fombellida-Lopez","year":"2025","journal-title":"Front Immunol"},{"issue":"23","key":"10.1016\/j.jinf.2026.106737_bib19","doi-asserted-by":"crossref","first-page":"9403","DOI":"10.1073\/pnas.0903107106","article-title":"Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy","volume":"106","author":"Dinoso","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.jinf.2026.106737_bib20","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/infdis\/jiq138","article-title":"A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response","volume":"203","author":"Hatano","year":"2011","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.jinf.2026.106737_bib21","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1086\/382488","article-title":"Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads","volume":"189","author":"Kieffer","year":"2004","journal-title":"J Infect Dis"},{"issue":"13","key":"10.1016\/j.jinf.2026.106737_bib22","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1128\/JVI.00591-06","article-title":"Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells","volume":"80","author":"Bailey","year":"2006","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.jinf.2026.106737_bib23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/infdis\/jir208","article-title":"Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy","volume":"204","author":"Chun","year":"2011","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2026.106737_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004677","article-title":"Residual viremia in treated HIV+ individuals","volume":"12","author":"Conway","year":"2016","journal-title":"PLoS Comput Biol"},{"issue":"13","key":"10.1016\/j.jinf.2026.106737_bib25","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1097\/QAD.0000000000003352","article-title":"Qualitative plasma viral load determination as a tool for screening of viral reservoir size in PWH","volume":"36","author":"Laeremans","year":"2022","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.jinf.2026.106737_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0030046","article-title":"ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia","volume":"3","author":"Maldarelli","year":"2007","journal-title":"PLoS Pathog"},{"issue":"10","key":"10.1016\/j.jinf.2026.106737_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110749","article-title":"Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients","volume":"9","author":"Hofstra","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jinf.2026.106737_bib28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/hiv.12323","article-title":"Determinants of residual viraemia during combination HIV treatment: impacts of baseline HIV RNA levels and treatment choice","volume":"17","author":"McKinnon","year":"2016","journal-title":"HIV Med"},{"issue":"3","key":"10.1016\/j.jinf.2026.106737_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213160","article-title":"Role of pretreatment variables on plasma HIV RNA value at the sixth month of antiretroviral therapy including all first line drugs in HIV na\u00cfve patients: a path analysis approach","volume":"14","author":"Mengoli","year":"2019","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jinf.2026.106737_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz177","article-title":"INSTI-based triple regimens in treatment-na\u00efve HIV-infected patients are associated with HIV-RNA viral load suppression at ultralow levels","volume":"6","author":"Lambert-Niclot","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"16","key":"10.1016\/j.jinf.2026.106737_bib31","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/01.aids.0000188426.87538.ed","article-title":"Residual viraemia in subjects with chronic HIV infection and viral load < 50copies\/ml: the impact of highly active antiretroviral therapy","volume":"19","author":"Palmisano","year":"2005","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.jinf.2026.106737_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29178","article-title":"Integrated analysis of viral blips, residual viremia, and associated factors in people with HIV: results from a retrospective cohort study","volume":"95","author":"Oomen","year":"2023","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.jinf.2026.106737_bib33","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijantimicag.2018.07.001","article-title":"Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies\/ml according to type of first-line antiretroviral regimen","volume":"52","author":"Gianotti","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jinf.2026.106737_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1128\/AAC.01902-19","article-title":"Detectability of HIV residual viremia despite therapy is highly associated with treatment with a protease inhibitor-based combination antiretroviral therapy","volume":"64","author":"Darcis","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2026.106737_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.982746","article-title":"The 2000HIV study: design, multi-omics methods and participant characteristics","volume":"13","author":"Vos","year":"2022","journal-title":"Front Immunol"},{"issue":"20","key":"10.1016\/j.jinf.2026.106737_bib36","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030606","article-title":"Traditional cardiovascular risk factors are stronger related to carotid intima-media thickness than to presence of carotid plaques in people living with HIV","volume":"12","author":"Blaauw","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jinf.2026.106737_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1459593","article-title":"Impact of COVID-19, lockdowns and vaccination on immune responses in a HIV cohort in the Netherlands","volume":"15","author":"Otten","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jinf.2026.106737_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2022.113307","article-title":"Comprehensive phenotyping of circulating immune cell subsets in people living with HIV","volume":"507","author":"Navas","year":"2022","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jinf.2026.106737_bib39","doi-asserted-by":"crossref","unstructured":"Delporte M, van Snippenberg W, Blomme EE,\u00a0Rutsaert S, Verschoore M, De Smet E, et al. Integrative assessment of total and intact HIV-1 reservoir by a five-region multiplexed Rainbow digital PCR assay. bioRxiv. 2023:2023.08.18.553846.","DOI":"10.1101\/2023.08.18.553846"},{"issue":"14","key":"10.1016\/j.jinf.2026.106737_bib40","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/eurjpc\/zwae174","article-title":"Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions","volume":"31","author":"Hageman","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"10.1016\/j.jinf.2026.106737_bib41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.arcmed.2015.05.006","article-title":"Infection and atherosclerosis development","volume":"46","author":"Campbell","year":"2015","journal-title":"Arch Med Res"},{"issue":"7","key":"10.1016\/j.jinf.2026.106737_bib42","doi-asserted-by":"crossref","first-page":"240","DOI":"10.12998\/wjcc.v2.i7.240","article-title":"Infectious burden and atherosclerosis: a clinical issue","volume":"2","author":"Sessa","year":"2014","journal-title":"World J Clin Cases"},{"issue":"10","key":"10.1016\/j.jinf.2026.106737_bib43","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3390\/v13101935","article-title":"Roles of virion-incorporated CD162 (PSGL-1), CD43, and CD44 in HIV-1 infection of T cells","volume":"13","author":"Murakami","year":"2021","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.jinf.2026.106737_bib44","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1128\/jvi.71.5.3588-3596.1997","article-title":"Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity","volume":"71","author":"Fortin","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.jinf.2026.106737_bib45","unstructured":"Prigann J, Tavora R, Furler O\u2019Brien RL, Schulze-Gahmen U, Boehm D, Roan NR, et al. Silencing the transcriptionally active HIV reservoir to improve treatment outcomes."},{"key":"10.1016\/j.jinf.2026.106737_bib46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/v14091980","article-title":"Forging a functional cure for HIV: transcription regulators and inhibitors","volume":"14","author":"Mediouni","year":"2022","journal-title":"Viruses"},{"issue":"21","key":"10.1016\/j.jinf.2026.106737_bib47","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1161\/CIRCULATIONAHA.113.001278","article-title":"Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice","volume":"127","author":"Cipriani","year":"2013","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jinf.2026.106737_bib48","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/j.1476-5381.2010.01147.x","article-title":"Chemokine receptor CCR5: from AIDS to atherosclerosis","volume":"162","author":"Jones","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jinf.2026.106737_bib49","unstructured":"Benlarbi M, Richard J, Bourassa C, Tolbert WD, Chartrand-Lefebvre C, Gendron-Lepage G, et al. Plasma human immunodeficiency virus 1 soluble glycoprotein 120 association with correlates of immune dysfunction and inflammation in antiretroviral therapy-treated individuals with undetectable viremia. (1537-6613 (Electronic))."},{"key":"10.1016\/j.jinf.2026.106737_bib50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ofid\/ofz112","article-title":"Maraviroc intensification modulates atherosclerotic progression in HIV-suppressed patients at high cardiovascular risk. A randomized, crossover pilot study","volume":"6","author":"Francisci","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.jinf.2026.106737_bib51","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.healun.2007.02.006","article-title":"Inhibition of chemokine receptor CCR2 and CCR5 expression contributes to simvastatin-induced attenuation of cardiac allograft vasculopathy","volume":"26","author":"Yin","year":"2007","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.jinf.2026.106737_bib52","unstructured":"Kl\u00fcner LA-O, Oikonomou EA-O, Antoniades CA-O. Assessing cardiovascular risk by using the fat attenuation index in coronary CT angiography. (2638-6135 (Electronic))."},{"key":"10.1016\/j.jinf.2026.106737_bib53","unstructured":"Si-Mohamed SA-O, Boccalini S, Lacombe H, Diaw AA-O, Varasteh MA-O, Rodesch PA-O, et al. Coronary CT angiography with photon-counting CT: first-in-human results. (1527-1315 (Electronic))."},{"issue":"4","key":"10.1016\/j.jinf.2026.106737_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e06755","article-title":"Conceptualization of population-specific human functional immune-genomics projects to identify factors that contribute to variability in immune and infectious diseases","volume":"7","author":"Boahen","year":"2021","journal-title":"Heliyon"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326000629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326000629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:48:12Z","timestamp":1777898892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445326000629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0163445326000629"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106737","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Residual HIV viremia strongly increases cardiovascular disease incidence independent of classical risk factors","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106737"}}